Novo Nordisk Plans to Double Capacity After Wegovy Outpaces U.S. Supply by 30%
NVO•Novo Nordisk said Wegovy prescriptions outpaced supply by 30% within two weeks of its U.S. launch, marking the fastest debut in the GLP-1 category. CEO Lars Fruergaard Jørgensen announced plans to double injectable manufacturing capacity by Q4 2026 to address demand shortages.
1. Record-Breaking U.S. Launch
Wegovy achieved a 30% higher prescription volume than initial forecasts within its first two weeks on the U.S. market, making it the fastest GLP-1 therapy launch in Novo Nordisk’s history and significantly boosting early sales momentum.
2. Manufacturing Ramp-Up
CEO Lars Fruergaard Jørgensen detailed plans to double injectable production capacity by Q4 2026, with capital allocated to expanding existing facilities and accelerating new manufacturing lines to meet sustained U.S. demand.
